Role of Duloxetine as Adjuvant in Chemotherapy Induced Peripheral Neuropathic Pain-An Update

• Main Authors: Kalpajit Dutta (Author), Rakesh Garg (Author)
• Format: Book
• Published: Journal of Addiction Medicine and Therapeutic Science - Peertechz Publications, 2016-06-29.
• Subjects: Research Article
• Online Access: Connect to this object online.

<p>Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of many anticancer drugs such as platinum compounds, antitubulins (taxanes and vinca alkaloids), bortezomib and thalidomide [1]. CIPN may manifest as sensory symptoms in hands and feet, typically in a "glove and stocking" pattern; pain, numbness, tingling etc; or motor symptoms such as weakness, deficits in the cranial nerve or autonomic neuropathy [2]. Various pharmacological agents have been evaluated for management of CIPN and have been reported to have variable effects.These agents include amitriptyline, nortriptyline, venlafaxine, gabapentin,pregabaline, lamotrigine, gel mixture of baclofen, amitriptyline and ketamine. These agents have shown variable effects for management of CIPN. The studies have observed to have limited success because of insignificant relief in pain and paresthesia or no difference in pain scores with these drugs [3-7] (Table 1).<br></p>